Low-dose semaglutide ‘can reduce alcohol cravings’

Library image. Credit: Yui Mok/PA Wire

By Sarah Lowden & PA Media

Initial research has indicated that low-dose semaglutide injections can reduce alcohol craving and some drinking outcomes, prompting calls for a larger clinical trial to evaluate GLP-1RAs for alcohol use disorder.

A clinical trial involving 48 participants found the weekly jab semaglutide, also known as Ozempic and Wegovy, did not affect average drinks per day or the number of days on which they had a drink, but did reduce the amount they drank and their alcohol cravings.

Researchers said the study backs up anecdotal evidence from patients and doctors that semaglutide can lead to a sudden loss of longing for alcoholic drinks, and adds to a growing body of evidence that the drug may have benefits beyond weight loss or controlling diabetes.

Previous studies have suggested it cuts the risk of heart attack and stroke in overweight adults, and also plays a role in improving heart failure symptoms.

The new study comes after UK figures published last week showed deaths from alcohol have reached a record high.